

0300

LAHIVE
&
COCKFIELD
L L P

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DeCONTI, JR.
ANN LAMPORT HAMMITTE
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
PETER C. LAURO
JEANNE M. DIGIORGIO
DEBRA J. MILASINCIC, Ph.D.
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER

CYNTHIA L. KANIK, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
RICHA NAND
MICHAEL PHILLIPPS *
LISA M. DIROCCO
HATHAWAY P. RUSSELL **
MARIA LACCOTRIPE-ZACHARAKIS, Ph.D.
PETER A. DIMATTIA
VINCENT P. LOCCISANO
MERIDETH C. ARNOLD

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT

PATENT AGENTS
THEODORE R. WEST
SHAYNE Y. HUFF, Ph.D.
DANIEL B. KO

TECHNICAL SPECIALISTS
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
EUIHOON LEE
JENNIFER K. ROSENFELD
ALLAN TAMESHTIT, Ph.D.
CATHERINE E. McPHERSON
ERIC F. WAGNER, Ph.D.
SHAHID HASAN, Ph.D.
JACOB G. WEINTRAUB
JONATHAN M. SPARKS, Ph.D.
CRISTIN E. HOWLEY, Ph.D.

* Admitted in NY only
** Admitted in TX only

May 21, 2002

U.S. Patent and Trademark Office
Box Sequence
P.O. Box 2327
Arlington, VA 22202

Re: U.S. Patent Application Serial No. 09/726,470
Title: p21 PEPTIDES
Filed: November 29, 2000
Inventors: Daniella I. Zveleva *et al.*
Attorney Docket No.: CCI-014


Dear Sir:

1. Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 pages);
2. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure (1 page);
3. Diskette Containing Sequence Listing; and
4. A Pre-Paid Acknowledgment Postcard.

Please charge any necessary fees to our Deposit Account No. 12-0080. The undersigned requests any extensions of time necessary to respond. A duplicate of this sheet is enclosed.


Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on:

May 21, 2002
Date

Cynthia L. Kanik, Ph.D., Reg. No. 37,320

Respectfully submitted,

LAHIVE & COCKFIELD, LLP


Cynthia L. Kanik, Ph.D.
Reg. No. 37,320
Attorney for Applicants

11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Daniella I. Zheleva, et al.

Serial No.: 09/726,470

Filed: November 29, 2000

For : p21 Peptides

Attorney Docket No.: CCI-014



Group Art Unit: 1646

Examiner:

U.S. Patent and Trademark Office
Box Sequence
P.O. Box 2327
Arlington, VA 22202


Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202 on the date set forth below.

May 21, 2002

Date of Signature and of Mail Deposit

By:


Cynthia L. Kanik, Ph.D.
Reg. No. 37,320
Attorney for Applicants

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES


Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed from the U.S. Patent Office on March 21, 2002, enclosed is a diskette which contains a computer readable form of the Sequence Listing filed for the above-identified patent application. The Sequence Listing complies with the requirements of 37 C.F.R. § 1.821. The material on the enclosed diskette is identical in substance to the Sequence Listing

filed in the above above-identified patent application. The computer readable form of the Sequence Listing contained on the enclosed diskette is understood to comply with the requirements of § 1.824(d). No new matter has been added.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



Cynthia L. Kanik, Ph.D.
Registration No. 36,207
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400
(617) 742-4214

Date: May 21, 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/726,470	11/29/2000	Daniella I. Zheleva	CCI-014

000959
LAHIVE & COCKFIELD
28 STATE STREET
BOSTON, MA 02109



CONFIRMATION NO. 1635

FORMALITIES LETTER



OC000000007690808

Date Mailed: 03/21/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice **MUST** be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

CDNL FELCA STANDARD; PRT: 164 AA.
ID Q19602: 15-DEC-1998 (Rel. 37, Created)
DT 15-DEC-1998 (Rel. 37, Last sequence update)
DT 15-DEC-1998 (Rel. 37, Last annotation update)
DE Cyclin-dependent kinase inhibitor 1 (p21) (CDK-interacting protein 1).
GN CDKN1A OR CIP1 OR WAF1.
OS Felis silvestris catus (Cat).
OC Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Carnivora; Fissipedia; Felidae; Felis.
OX NCBI_TaxID=9685;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Lymph node;
RX MEDLINE=98036042; PubMed=9370275;
RA Okuda M., Minehata K., Setoguchi A., Cho K.-W., Nakamura N.,
RA Nishigaki K., Watarai T., Cevario S., O'Brien S.J., Tsujimoto H.,
RA Hasegawa A.;
RT "Cloning and chromosome mapping of the feline genes p21WAF1 and
p27Kip1".
RL Gene 198.141-147(1997).
CC -!- FUNCTION: MAY BE THE IMPORTANT INTERMEDIATE BY WHICH P53 MEDIATES
CC ITS ROLE AS AN INHIBITOR OF CELLULAR PROLIFERATION IN RESPONSE TO
CC DNA DAMAGE. MAY BIND TO AND INHIBIT CYCLIN-DEPENDENT KINASE
CC ACTIVITY, PREVENTING PHOSPHORYLATION OF CRITICAL CYCLIN-DEPENDENT
CC KINASE SUBSTRATES AND BLOCKING CELL CYCLE PROGRESSION (BY
CC SIMILARITY).
CC -!- SUBCELLULAR LOCATION: Nuclear.
CC -!- SIMILARITY: THE N-TERMINAL OF CIP1 AND KIP ARE SIMILAR.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC
CC EMBL: D84650; BAA23168.1;
DR InterPro: IPR003175; CDI.
DR Pfam: PF02234; CDI; 1.
KW Cell cycle; Nuclear protein; Zinc-finger.
FT ZN_FING 13 41
FT DOMAIN 141 156 NUCLEAR LOCALIZATION SIGNAL (POTENTIAL).
SQ SEQUENCE 164 AA; 18315 MW; 0F7912A76C78BF38 CRC64;

Query Match 92.7%; Score 38; DB 1; Length 164;
Best Local Similarity 87.5%; Pred. No. 0.11;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAKRRLIF 8
|:|||||
Db 152 HSKRRLIF 159

Cyclin kinase inhibitor - human (fragments)
C:Species: Homo sapiens (map)
C:Date: 25-Feb-1994 #sequence_revision 17-Nov-1995 #text_change 17-Mar-1999
C:Accession: S39358
R:Xiong, Y.; Hannon, G.J.; Zhang, H.; Casso, D.; Kobayashi, R.; Beach, D.
Nature 366, 701-704, 1993
A:Title: p21 is a universal inhibitor of cyclin kinases.
A:Reference number: S39357; MUID:94081955; PMID:8259214
A:Accession: S39358
A:Status: preliminary
A:Molecule type: protein
A:Residues: 1-47 <XIO>

Query Match 92.7%; Score 38; DB 2; Length 47;
Best Local Similarity 87.5%; Pred. No. 0.28;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAKRRLIF 8
|:|||||
Db 38 HSKRRLIF 45

RESULT 2

154380

cyclin-dependent kinase - human (fragment)

C:Species: Homo sapiens (man)

C:Date: 02-Jul-1996 #sequence_revision 02-Jul-1996 #text_change 21-Jul-2000

C:Accession: 154380

R:Mousses, S.; Ozelik, H.; Lee, P.D.; Malkin, D.; Bull, S.B.; Andrulis, I.L.

Hum. Mol. Genet. 4, 1089-1092, 1995

A:Title: Two variants of the CIP1/WAF1 gene occur together and are associated with h

A:Reference number: 154380; MUID:95384154; PMID:7655464

A:Accession: 154380

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: mRNA

A:Residues: 1-181 <RES>

A:Cross-references: GB:L47232; NID:984723; PIDN:AAB59559.1; PID:g984724

C:Genetics:

A:Gene: CIP1/WAF1

Query Match 92.7%; Score 38; DB 2; Length 181;
Best Local Similarity 87.5%; Pred. No. 0.98;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAKRRLIF 8
|:|||||
Db 169 HSKRRLIF 176

RESULT 1

Q14010

ID Q14010 PRELIMINARY; PRT: 181 AA.

AC Q14010;

DT 01-NOV-1996 (TRENDEL. 01, Created)

DT 01-NOV-1996 (TRENDEL. 01, Last sequence update)

DT 01-DEC-2001 (TRENDEL. 19, Last annotation update)

DE Cyclin-dependent kinase (Fragment).

GN CIP1/WAF1.

OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

OX NCBI_TaxID=9606;

RN [1]

RP SEQUENCE FROM N.A.

RC TISSUE=TUMOR;

RX MEDLINE=95384154; PubMed=7655464;

RA Mousses S., Ozelik H., Lee P.D., Malkin D., Bull S.B., Andrulis I.L.;

RT "Two variants of the CIP1/WAF1 gene occur together and are associated

RT with human cancer."

RL Hum. Mol. Genet. 4:1089-1092(1995).

DR EMBL: L47232; AAB59559.1;

DR InterPro: IPR003175; CDI.

DR Pfam: PF02234; CDI; 1.

KW Kinase.

FT NON_TER 1

SQ SEQUENCE 181 AA; 20083 MW; 4CCFA51123232D4F1 CRC64;

Query Match 92.7%; Score 38; DB 4; Length 181;
Best Local Similarity 87.5%; Pred. No. 1.8;
Matches 7; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 HAKRRLIF 8
|:|||||